Injury prevention by medication among children with attention-deficit/Hyperactivity disorder a case-only study

JAMA Pediatrics

Volumn 169, Issue 4, 2015, Pages 391-395

  Mikolajczyk, Rafael ^a,b,c   Horn, Johannes ^a,b   Schmedt, Niklas ^a   Langner, Ingo ^a   Lindemann, Christina ^a,c   Garbe, Edeltraut ^a,d  

^a LEIBNIZ INSTITUTE FOR PREVENTION RESEARCH AND EPIDEMIOLOGY BIPS   (Germany)

^b HELMHOLTZ CENTRE FOR INFECTION RESEARCH   (Germany)

^c HANNOVER MEDICAL SCHOOL   (Germany)

^d UNIVERSITY OF BREMEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ATOMOXETINE; METHYLPHENIDATE; ADRENERGIC RECEPTOR AFFECTING AGENT; CENTRAL STIMULANT AGENT; PROPYLAMINE;

ACCIDENT PREVENTION; ADOLESCENT; ARTICLE; ATTENTION DEFICIT DISORDER; BRAIN INJURY; CASE STUDY; CHILD; CHILD HOSPITALIZATION; CHILDHOOD MORTALITY; FEMALE; FOLLOW UP; GERMANY; HEALTH INSURANCE; HOSPITAL PATIENT; HUMAN; ICD-10; INJURY; MAJOR CLINICAL STUDY; MALE; OUTPATIENT; PHARMACOEPIDEMIOLOGY; PRESCRIPTION; PRIORITY JOURNAL; RISK REDUCTION; SCHOOL CHILD; SENSITIVITY ANALYSIS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; BRAIN INJURIES; COMPLICATION; HOSPITALIZATION; INCIDENCE; PRESCHOOL CHILD; RISK; STATISTICS AND NUMERICAL DATA; WOUNDS AND INJURIES;

ADOLESCENT; ADRENERGIC UPTAKE INHIBITORS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; BRAIN INJURIES; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; CHILD, PRESCHOOL; GERMANY; HOSPITALIZATION; HUMANS; INCIDENCE; METHYLPHENIDATE; PROPYLAMINES; RISK; WOUNDS AND INJURIES;

EID: 84928253784     PISSN: 21686203     EISSN: 21686211     Source Type: Journal    
DOI: 10.1001/jamapediatrics.2014.3275     Document Type: Article

References (34)

1. Biederman J, Faraone SV. Attention-deficit hyperactivity disorder. Lancet. 2005;366(9481): 237-248
2. Brehaut JC, Miller A, Raina P, McGrail KM. Childhood behavior disorders and injuries among children and youth: a population-based study. Pediatrics. 2003;111(2):262-269
3. DiScala C, Lescohier I, Barthel M, Li G. Injuries to children with attention deficit hyperactivity disorder. Pediatrics. 1998;102(6):1415-1421
4. Marcus SC,Wan GJ, Zhang HF, Olfson M. Injury among stimulant-treated youth with ADHD. J Atten Disord. 2008;12(1):64-69
5. Merrill RM, Lyon JL, Baker RK, Gren LH. Attention deficit hyperactivity disorder and increased risk of injury. Adv Med Sci. 2009;54(1):20-26
6. Rowe R, Maughan B, Goodman R. Childhood psychiatric disorder and unintentional injury: findings from a national cohort study. J Pediatr Psychol. 2004;29(2):119-130
7. Swensen A, Birnbaum HG, Ben Hamadi R, Greenberg P, Cremieux PY, Secnik K. Incidence and costs of accidents among attention-deficit/hyperactivity disorder patients. J Adolesc Health. 2004;35(4):346.e1-346.e9
8. Kang JH, Lin HC, Chung SD. Attention-deficit/hyperactivity disorder increased the risk of injury: a population-based follow-up study. Acta Paediatr. 2013;102(6):640-643
9. Pastor PN, Reuben CA. Identified attention-deficit/hyperactivity disorder and medically attended, nonfatal injuries: US school-age children, 1997-2002. Ambul Pediatr. 2006;6(1): 38-44
10. Bruce B, Kirkland S,Waschbusch D. The relationship between childhood behaviour disorders and unintentional injury events. Paediatr Child Health. 2007;12(9):749-754
11. Fliers E, Rommelse N, Vermeulen SH, et al. Motor coordination problems in children and adolescents with ADHD rated by parents and teachers: effects of age and gender. J Neural Transm. 2008;115(2):211-220
12. Flapper BC, Houwen S, Schoemaker MM. Fine motor skills and effects ofmethylphenidate in children with attention-deficit-hyperactivity disorder and developmental coordination disorder. Dev Med Child Neurol. 2006;48(3):165-169
13. Pless IB, Taylor HG, Arsenault L. The relationship between vigilance deficits and traffic injuries involving children. Pediatrics. 1995; 95(2):219-224
14. Winterstein AG, Gerhard T, Shuster J, et al. Utilization of pharmacologic treatment in youths with attention deficit/hyperactivity disorder in Medicaid database. Ann Pharmacother. 2008;42 (1):24-31
15. Zito JM, Safer DJ, dosReis S, Gardner JF, Boles M, Lynch F. Trends in the prescribing of psychotropic medications to preschoolers. JAMA. 2000;283(8):1025-1030
16. Hodgkins P, Sasané R, Meijer WM. Pharmacologic treatment of attention-deficit/hyperactivity disorder in children: incidence, prevalence, and treatment patterns in the Netherlands. Clin Ther. 2011;33(2):188-203
17. Garbe E, Mikolajczyk RT, Banaschewski T, et al. Drug treatment patterns of attention-deficit/hyperactivity disorder in children and adolescents in Germany: results from a large population-based cohort study. J Child Adolesc Psychopharmacol. 2012;22(6):452-458
18. Jerome L, Segal A, Habinski L. What we know about ADHD and driving risk: a literature review, meta-analysis and critique. J Can Acad Child Adolesc Psychiatry. 2006;15(3):105-125
19. Thompson AL, Molina BS, PelhamWJr, Gnagy EM. Risky driving in adolescents and young adults with childhood ADHD. J Pediatr Psychol. 2007;32(7):745-759
20. Barkley RA, Cox D. A review of driving risks and impairments associated with attention-deficit/hyperactivity disorder and the effects of stimulant medication on driving performance. J Safety Res. 2007;38(1):113-128
21. Sobanski E, Sabljic D, Alm B, et al. Driving-related risks and impact of methylphenidate treatment on driving in adults with attention-deficit/hyperactivity disorder (ADHD). J Neural Transm. 2008;115(2):347-356
22. van den Ban E, Souverein P, MeijerW, et al. Association between ADHD drug use and injuries among children and adolescents. Eur Child Adolesc Psychiatry. 2014;23(2):95-102
23. LageM, Hwang P. Effect of methylphenidate formulation for attention deficit hyperactivity disorder on patterns and outcomes of treatment. J Child Adolesc Psychopharmacol. 2004;14(4): 575-581
24. Kemner JE, LageMJ. Impact of methylphenidate formulation on treatment patterns and hospitalizations: a retrospective analysis. Ann Gen Psychiatry. 2006;5:5
25. Garbe E, SulingM, Kloss S, Lindemann C, Schmid U. Linkage of mother-baby pairs in the German Pharmacoepidemiological Research Database. Pharmacoepidemiol Drug Saf. 2011;20(3): 258-264
26. Pigeot I, AhrensW. Establishment of a pharmacoepidemiological database in Germany: methodological potential, scientific value and practical limitations. Pharmacoepidemiol Drug Saf. 2008;17(3):215-223
27. Lindemann C, Langner I, Kraut AA, et al. Age-specific prevalence, incidence of new diagnoses, and drug treatment of attention-deficit/hyperactivity disorder in Germany. J Child Adolesc Psychopharmacol. 2012;22(4): 307-314
28. Kraut AA, Langner I, Lindemann C, et al. Comorbidities in ADHD children treated with methylphenidate: a database study. BMC Psychiatry. 2013;13:11
29. Fingerhut LA,Warner M. The ICD-10 injury mortality diagnosis matrix. Inj Prev. 2006;12(1): 24-29
30. Farrington CP. Relative incidence estimation from case series for vaccine safety evaluation. Biometrics. 1995;51(1):228-235
31. Whitaker H. Using SAS for the self-controlled case seriesmethod. http://statistics.open.ac.uk/sccs/sas.htm. Accessed June 4, 2014
32. Raman SR, Marshall SW, Haynes K, Gaynes BN, Naftel AJ, Stürmer T. Stimulant treatment and injury among children with attention deficit hyperactivity disorder: an application of the self-controlled case series study design. Inj Prev. 2013;19(3):164-170
33. Tai YM, Gau SS, Gau CS. Injury-proneness of youth with attention-deficit hyperactivity disorder: a national clinical data analysis in Taiwan. Res Dev Disabil. 2013;34(3):1100-1108
34. Scharnetzky E, SchillW, Glaeske G, Jahnsen K. Are children and youths with attention-deficit/hyperactivity disorder (ADHD) accident prone? Presented at: 11th Meeting of the German Society for Drug Use Research and Drug Epidemiology; September 30-October 1, 2004; Jena, Germany. http://www.egms.de/de/meetings/gaa2004/04gaa24.shtml. Accessed January 5, 2015.